ACHN:NSD-Achillion Pharmaceuticals, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 110.00

Change

0.00 (0.00)%

Market Cap

USD 0.95B

Volume

30.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Company Website : http://www.achillion.com

Address : 300 George Street 06511,New Haven,USA

Employees : 56

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.59

52 Week High : 138.99

52 Week Low : 103.00

Shorted Shares : 8,603,331

200 Day Moving Average : 5.74

Shorted Shares Previous Month : 8,832,343

50 Day Moving Average : 6.76

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing ACHN

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1,724.21% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,724.21% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 2,825.53% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,825.53% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 1,427.78% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,427.78% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 264.76% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 264.76% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 920.23% N/A N/A N/A N/A
Risk Adjusted Return 28.77% N/A N/A N/A N/A
Market Capitalization 0.95B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.36 N/A N/A N/A N/A
Price / Cash Flow Ratio -15.27 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -25.05% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.59 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.